Since completing treatment with IL-2, he has undergone a surveillance PET CT scan 6 months after the last dose of IL-2, which revealed no definitive active disease, and biopsies of two separate persistent lesions demonstrated fibrosis without evidence of porocarcinoma. The gene discussed is IL2; the disease is eccrine porocarcinoma.